A Phase 2 interventional study of migalastat HCl in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 6 sites in 6 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-03.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 16th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 4th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2006.
This study's enrollment of 9 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2006, is one of 6 in phase 2, and was the 4th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
This was a Phase 2, open-label study in female participants with Fabry disease. The study consisted of a 4-week screening period, during which participants' galactosidase (GLA) genotype was assessed for α-galactosidase A (α-Gal A) activity in response to migalastat. Participants were required to have α-Gal A activity responsive to migalastat. The study consisted of a 12-week treatment period, followed by an optional 36-week extension period. Participants received migalastat once every other day (QOD) for 12 weeks during the treatment period and the optional 36-week extension period for a total treatment duration of up to 48 weeks. Participants were stratified by α-Gal A enzyme activity (high >40%, and low ≤40%) then randomly assigned to receive migalastat at 1 of 3 specified dose levels (50, 150, or 250 milligrams [mg]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
Drug: migalastat HCl
Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
Drug: migalastat HCl
Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
Drug: migalastat HCl
Also known as: AT1001, Galafold, migalastat
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 48 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Day 1 (after dosing) through Week 48
PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat
The AUC to the last measurable concentration (AUC0-t) was evaluated in plasma following a single oral dose of migalastat on Day 1 and following multiple oral doses on Day 14 (2 weeks) and Day 84 (12 weeks). All samples were collected on each dosing day.
Time frame: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hours (postdose)
α-Gal A Activity In Leukocytes At Baseline, Week 12, And Week 48
Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.
Time frame: Baseline, Week 12 (end of treatment period), Week 48 (end of extension period)
| Milestone | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| Started | 2 | 4 | 3 |
| Safety population | 2 | 4 | 3 |
| Pharmacokinetic (pk) population | 2 | 4 | 3 |
| Pharmacodynamic (pd) population | 2 | 4 | 3 |
| Completed | 2 | 4 | 3 |
| Not completed | 0 | 0 | 0 |
| Milestone | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| Started | 2 | 4 | 3 |
| Completed | 2 | 4 | 3 |
| Not completed | 0 | 0 | 0 |
TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 48 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) | 0 | 0 | 0 |
The AUC to the last measurable concentration (AUC0-t) was evaluated in plasma following a single oral dose of migalastat on Day 1 and following multiple oral doses on Day 14 (2 weeks) and Day 84 (12 weeks). All samples were collected on each dosing day.
| nanograms*hours/milliliters (ng*hr/mL) | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| AUC0-t: Single Dose, Day 1 | 2628.9 ± 100.4 | 8941.6 ± 32.2 | 13217.2 ± 30.2 |
| AUC0-t: Multiple Dose, Day 14 | 3191.6 ± 64.9 | 10637.9 ± 35.6 | 14850.6 ± 9.6 |
| AUC0-t: Multiple Dose, Day 84 | 2300.3 ± 79.6 | 8581.9 ± 29.7 | 9970.3 ± 37.8 |
Leukocytes were isolated from whole blood and lysed, and α-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole \[nmol\] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. α-Gal A activity in leukocytes are presented by individual participants.
| nmol 4-MU/hr/mg protein | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| Participant 1: Baseline | 13.4 | — | — |
| Participant 1: Week 12 | 2.46 | — | — |
| Participant 1: Week 48 | 26 | — | — |
| Participant 2: Baseline | 24.5 | — | — |
| Participant 2: Week 12 | 35.8 | — | — |
| Participant 2: Week 48 | 39.6 | — | — |
| Participant 3: Baseline | — | 25.1 | — |
| Participant 3: Week 12 | — | 4.15 | — |
| Participant 3: Week 48 | — | NA | — |
| Participant 4: Baseline | — | 6.39 | — |
| Participant 4: Week 12 | — | 18.4 | — |
| Participant 4: Week 48 | — | 16.1 | — |
| Participant 5: Baseline | — | 17.3 | — |
| Participant 5: Week 12 | — | 5.85 | — |
| Participant 5: Week 48 | — | 22.2 | — |
| Participant 6: Baseline | — | 24.6 | — |
| Participant 6: Week 12 | — | 12.6 | — |
| Participant 6: Week 48 | — | 46.5 | — |
| Participant 7: Baseline | — | — | 3.25 |
| Participant 7: Week 12 | — | — | 6.56 |
| Participant 7: Week 48 | — | — | 4.83 |
| Participant 8: Baseline | — | — | 14.7 |
| Participant 8: Week 12 | — | — | 23.3 |
| Participant 8: Week 48 | — | — | 29.2 |
| Participant 9: Baseline | — | — | 13.1 |
| Participant 9: Week 12 | — | — | 8.86 |
| Participant 9: Week 48 | — | — | 7.58 |
Collected over Day 1 after dosing through Week 48 (end of extension period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Migalastat Low Dose 50 mg | — | 0/2 (0%) | 2/2 (100%) |
| Migalastat Middle Dose 150 mg | — | 1/4 (25%) | 4/4 (100%) |
| Migalastat High Dose 250 mg | — | 0/3 (0%) | 3/3 (100%) |
| Event | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/2 | 1/4 | 0/3 |
| Event | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 1/2 | 3/4 | 0/3 |
| Sinus arrhythmiaCardiac disorders | 1/2 | 0/4 | 0/3 |
| Abdominal discomfortGastrointestinal disorders | 1/2 | 0/4 | 0/3 |
| Abdominal painGastrointestinal disorders | 1/2 | 1/4 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 0/4 | 0/3 |
| NauseaGastrointestinal disorders | 1/2 | 0/4 | 0/3 |
| VomitingGastrointestinal disorders | 1/2 | 1/4 | 0/3 |
| Face oedemaGeneral disorders | 1/2 | 0/4 | 0/3 |
| Oedema peripheralGeneral disorders | 1/2 | 1/4 | 0/3 |
| Bronchitis acuteInfections and infestations | 1/2 | 0/4 | 0/3 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg | Total |
|---|---|---|---|---|
| Mean | 49.0 ± 18.38 | 44.8 ± 9.95 | 44.0 ± 2.65 | 45.4 ± 9.23 |
| Sex: Female, Male(Participants) | Migalastat Low Dose 50 mg | Migalastat Middle Dose 150 mg | Migalastat High Dose 250 mg | Total |
|---|---|---|---|---|
| Female | 2 | 4 | 3 | 9 |
| Male | 0 | 0 | 0 | 0 |
Ran from Sep 2006 to primary completion in May 2008, 20 months.
Results were first posted in Sep 2018, 10 years 3 months after primary completion. A results delay was requested in Aug 2010.
Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat